Niu, Siqiang Chavda, Kalyan D Wei, Jie Zou, Chunhong Marshall, Steven H Dhawan, Puneet Wang, Deqiang Bonomo, Robert A Kreiswirth, Barry N Chen, Liang
...
Published in
mSphere
Ceftazidime-avibactam is a potent antibiotic combination against Klebsiella pneumoniae carbapenemase (KPC)-producing Enterobacteriaceae Here, we describe a unique ceftazidime-avibactam-resistant and carbapenem-susceptible K. pneumoniae strain harboring a novel bla KPC-14 variant. This strain was isolated from a New York City patient in 2003, which ...
Yasmin, Mohamad Hanrahan, Jennifer Marshall, Steven Lodise, Thomas P Chen, Liang Perez, Federico Kreiswirth, Barry Bonomo, Robert A
Published in
Open Forum Infectious Diseases
This report describes the treatment of Klebsiella pneumoniae carbapenemase (KPC)–3–producing multidrug-resistant K. pneumoniae with ceftazidime/avibactam (CAZ-AVI) in a patient who developed postneurosurgical meningitis and bacteremia. Therapeutic drug monitoring of cerebrospinal fluid and blood samples demonstrated CAZ-AVI concentration levels 20-...
Yasmin, Mohamad Fouts, Derrick E Jacobs, Michael R Haydar, Hanan Marshall, Steven H White, Richard D'Souza, Roshan Lodise, Thomas P Rhoads, Daniel D Hujer, Andrea M
...
Published in
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
In an infection with an Enterobacter sp. isolate producing Klebsiella pneumoniae Carbapenemase-4 and New Delhi Metallo-β-Lactamase-1 in the United States, recognition of the molecular basis of carbapenem resistance allowed for successful treatment by combining ceftazidime-avibactam and aztreonam. Antimicrobial synergy testing and therapeutic drug m...
Shields, Ryan K McCreary, Erin K Marini, Rachel V Kline, Ellen G Jones, Chelsea E Hao, Binghua Chen, Liang Kreiswirth, Barry N Doi, Yohei Clancy, Cornelius J
...
Published in
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Twenty patients with carbapenem-resistant Enterobacteriaceae infections were treated with meropenem-vaborbactam. Thirty-day clinical success and survival rates were 65% (13/20) and 90% (18/20), respectively. Thirty-five percent of patients had microbiologic failures within 90 days. One patient developed a recurrent infection due to meropenem-vaborb...
Poirel, Laurent Vuillemin, Xavier Juhas, Mario Masseron, Amandine Bechtel-Grosch, Ursina Tiziani, Simon Mancini, Stefano Nordmann, Patrice
Published in
Antimicrobial Agents and Chemotherapy
KPC-50 is a KPC-3 variant identified from a Klebsiella pneumoniae clinical isolate recovered in Switzerland in 2019. Compared to KPC-3, KPC-50 shows (i) a three-amino-acid insertion (Glu-Ala-Val) between amino acids 276 and 277, (ii) an increased affinity to ceftazidime, (iii) a decreased sensitivity to avibactam, explaining the ceftazidime-avibact...
Zaragoza, Rafael Vidal-Cortés, Pablo Aguilar, Gerardo Borges, Marcio Diaz, Emili Ferrer, Ricard Maseda, Emilio Nieto, Mercedes Nuvials, Francisco Xavier Ramirez, Paula
...
Published in
Critical Care
In accordance with the recommendations of, amongst others, the Surviving Sepsis Campaign and the recently published European treatment guidelines for hospital-acquired pneumonia (HAP) and ventilator-associated pneumonia (VAP), in the event of a patient with such infections, empirical antibiotic treatment must be appropriate and administered as earl...
Cui, Xiaoyan Shan, Bin Zhang, Xue Qu, Fen Jia, Wei Huang, Bin Yu, Hua Tang, Yi-Wei Chen, Liang Du, Hong
...
Published in
Frontiers in Microbiology
KPC-producing Klebsiella pneumoniae (KPC-KP) is the most widely spread carbapenem-resistant Enterobacteriaceae (CRE) in China. Avibactam is a novel non-β-lactam β-lactamase inhibitor which is highly active against KPC. Recently, ceftazidime-avibactam (CAZ-AVI) was approved for clinical treatment in China. Here we conducted a retrospective study to ...
Thapa Shrestha, Upendra Shrestha, Sabnum Adhikari, Nabaraj Rijal, Komal Raj Shrestha, Basudha Adhikari, Bipin Banjara, Megha Raj Ghimire, Prakash
Published in
Infection and drug resistance
Extended-spectrum β-lactamases (ESBL) among Gram-negative bacteria, predominantly Escherichia coli (E. coli), in Nepal, have been rising. The main objectives of this study were to determine the prevalence of uropathogenic E. coli, antibiotic resistance, ESBLs, ABLs (AmpC type β-lactamases), MBLs (metallo-β-lactamases) and KPCs (Klebsiella pneumonia...
Zhu, Jiaying Li, Qi Li, Xiaoxia Kang, Jianbang Song, Yan Song, Junli Yin, Donghong Duan, Jinju
Published in
Antimicrobial Resistance & Infection Control
BackgroundCarbapenem-resistant Klebsiella pneumoniae (CRKP) is considered as a serious global threat. CRKPs occurred only sporadically in the Second Hospital of Shanxi Medical University. Our study aimed to investigate and control the first outbreak of CRKP in our hospital occurred between October 2017 and August 2019.MethodsThe antimicrobial stewa...
Navarro, Miguel Octavio Pérez Dilarri, Guilherme Simionato, Ane Stefano Grzegorczyk, Kathlen Dealis, Mickely Liuti Cano, Barbara Gionco Barazetti, André Riedi Afonso, Leandro Chryssafidis, Andreas Lazaros Ferreira, Henrique
...
Published in
Frontiers in Microbiology
The antibiotic activity of metalloantibiotic compounds has been evaluated since the 90s, and many different modes of action were characterized. In the last decade, the effects of secondary metabolites produced by Pseudomonas aeruginosa LV strain, including a cupric compound identified as Fluopsin C, were tested against many pathogenic bacteria stra...
